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Introduction: Recent clinical trials incorporating maintenance che-
motherapy into the initial treatment of advanced non-small cell lung
cancer (NSCLC) have highlighted the benefits of exposing patients
to second-line therapies. We, therefore, determined the predictors
and impact of second-line chemotherapy administration in a con-
temporary, diverse NSCLC population.
Methods: We performed a retrospective analysis of consecutive
patients diagnosed with stage IV NSCLC from 2000 to 2007 at
clinical facilities associated with the University of Texas Southwest-
ern Medical Center. Demographic, disease, treatment, and outcome
data were obtained from hospital tumor registries. The association
between these variables was assessed using univariate analysis and
multivariate logistic regression.
Results: A total of 406 patients in this cohort received first-line
chemotherapy and were included in the analysis. Mean age was 59
years, 28% were women, and 59% were white. Among these
patients, 197 (49%) received second-line chemotherapy. Among
those patients who had not progressed after four to six cycles of
first-line chemotherapy, 67% received second-line chemotherapy.
Receipt of second-line chemotherapy was significantly associated
with patient insurance type (p  0.007), number of cycles of
first-line chemotherapy (p 0.001), and receipt of prechemotherapy
palliative radiation therapy (p  0.005) but was not associated with
patient age, gender, race, histology, or year of diagnosis. In a
multivariate model, second-line chemotherapy administration re-
mained associated with insurance type (p  0.003), number of
cycles of first-line chemotherapy (p  0.001), and receipt of pre-
chemotherapy palliative radiation therapy (p  0.008). The number
of cycles of first-line chemotherapy and administration of second-
line chemotherapy were associated with overall survival in both
univariate and multivariate analyses.
Conclusions: In this unselected, contemporary, and diverse cohort
of patients with advanced NSCLC, 67% of individuals whose
disease had not progressed after four to six cycles of first-line
chemotherapy eventually received second-line chemotherapy. Mark-
ers of socioeconomic status, symptom burden, and response to and
tolerance of first-line chemotherapy were associated with receipt of
second-line chemotherapy. These factors may assist in the selection
of patients most likely to benefit from maintenance chemotherapy.
Key Words: Non-small cell lung cancer, Metastatic, Second-line
chemotherapy, Maintenance chemotherapy, Practice patterns, Radi-
ation therapy, Insurance.
(J Thorac Oncol. 2011;6: 365–371)
The role of second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) has been highlighted by
a number of recent clinical trials examining the role of
“maintenance” therapy.1–6 Traditionally, patients with re-
sponsive or stable disease after four to six cycles of first-line
platinum doublet chemotherapy have been monitored clini-
cally and radiographically off therapy, with second-line che-
motherapy initiated on disease progression. Currently, three
agents—docetaxel, pemetrexed, and erlotinib—are approved
for this indication in the United States.7–9 With mainte-
nance therapy, patients receive subsequent treatment im-
mediately after completing first-line chemotherapy, either
with a new agent (“switch maintenance”)2,4–5,10 or with an
agent given during first-line therapy (“continuation main-
tenance”).1,5 Across studies, maintenance chemotherapy
has been associated with prolongation of progression-free
survival. Some trials have also demonstrated improvement
in overall survival.2,10
Clinical trials of maintenance chemotherapy have been
noteworthy for widely varying rates of second-line chemo-
therapy administration. Among patients randomized to obser-
vation after completion of first-line treatment, anywhere from
17 to 82% of patients received second-line therapy on disease
progression; 3 to 63% of patients received the same agent
given in the maintenance arm.1,4–5 These discrepancies have
confounded the interpretation of study results. It is not clear
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whether maintenance chemotherapy provides a benefit be-
cause of its timing or because it exposes more patients to
additional, potentially effective therapies. That is, if there
were a means to predict which patients would be fit to receive
second-line therapy at the time of progression, it might not be
necessary to offer these individuals maintenance regimens.
Outside the controlled environment of a clinical trial,
little is known about administration of second-line chemo-
therapy. Large administrative databases do not routinely
record this information. A recently published study from
South Korea reported that 86% of patients received second-
line treatment.11 This unusually high rate exceeds those of
prospective, randomized maintenance chemotherapy trials
and may reflect the young age and good performance status of
the patient population. Indeed, multiple lung cancer studies
have demonstrated substantial differences in treatment effects
and overall prognosis between East Asian and western pop-
ulations.12–16 To provide further insight into this issue, we
examined the predictors and impact of second-line chemo-
therapy administration at a large North American medical
center providing care to a diverse patient population within
three different hospital systems.
METHODS
Study Setting
The study cohort was captured from clinical facilities
associated with the University of Texas Southwestern Med-
ical Center (UT Southwestern), including Parkland Health
and Hospital System (PHHS), University Hospital (which
includes the freestanding Harold C. Simmons Cancer Center),
and the Dallas Veterans Affairs (VA) Medical Center. PHHS
consists of a 968-bed public hospital and outpatient clinics
that provide health care to predominantly indigent and unin-
sured residents of Dallas County. Dallas County is the ninth
most populous county in the United States, with an estimated
2.4 million residents, of whom 39% are Hispanic, 35% are
white, and 21% are African American.17 University Hospital
(415 beds) is the principal medical and surgical referral
hospital for UT Southwestern. The Dallas VA, a 289-bed
hospital and outpatient clinics, serves as the principal tertiary
care center for military veterans in a 40-county region of
Northern Texas and Southern Oklahoma. It provides full
medical, radiation, and surgical oncology services.
Data Extraction
This study was approved by the UT Southwestern and
the VA North Texas Health Care System Institutional Review
Boards. We identified patients diagnosed with stage IV
NSCLC between January 1, 2000, and December 31, 2007, in
the UT Southwestern, PHHS, and Dallas VA tumor registries.
Additional information was obtained through electronic and
paper medical records. The tumor registries identify cases
through review of pathology records, clinic schedules, and
hospital admission and discharge records. Certified tumor
registrars extract data directly from medical records accord-
ing to standards established by the American College of
Surgeons Commission on Cancer, Surveillance Epidemiol-
ogy and End Results/National Cancer Institute, and the Na-
tional Program of Cancer Registries. Multiple data fields are
collected per patient, including demographics, cancer diag-
nosis and stage, treatment, and follow-up. After initial cancer
diagnosis and treatment, the tumor registries contact patients
and their medical providers every 6 months for follow-up
data. These data are then reported to the Texas State Cancer
Registry and to the Commission on Cancer’s National Cancer
Database.
We limited our study period to the years 2000–2007 for
the following reasons: (1) randomized clinical trial data
supporting the use of second-line chemotherapy for advanced
NSCLC was first published in 20007; (2) adequate data were
first recorded by UT Southwestern-associated tumor regis-
tries in 2000; (3) maintenance chemotherapy for advanced
NSCLC was not incorporated into clinical practice during this
period; and (4) the 2007 cutoff provides sufficient follow-up
time for survival outcomes. We included only those patients
who received platinum-based doublet chemotherapy as first-
line treatment, as a survival benefit of second-line or main-
tenance chemotherapy has not been demonstrated for patients
treated with single-agent first-line regimens.
Recording and Definition of Variables
For each patient, the following demographic data were
recorded: age, gender, race/ethnicity, and insurance type.
Race/ethnicity was categorized as white (non-Hispanic), His-
panic, African American, or other. Insurance type was re-
corded as one of the following: no insurance, Medicaid (a
federal/state health care program for low-income families),
Medicare (a federal health care program for individuals aged
65 years and older), VA, and private. The designation “no
insurance” primarily includes individuals ultimately treated
through a Dallas County public health plan that provides
patients access to all standard diagnostic and treatment mo-
dalities. Disease variables recorded included tumor histology,
date of diagnosis, and date of death or last known follow-up.
Histology was categorized as adenocarcinoma, squamous cell
carcinoma, or other. Overall survival was defined as the
interval between date of diagnosis and date of death.
We recorded the following treatment variables: receipt
of palliative radiotherapy before initiation of first-line che-
motherapy (and site irradiated), number of cycles of first-line
chemotherapy, disease status at the end of first-line chemo-
therapy, and receipt of second-line chemotherapy. For pa-
tients who received at least four cycles of first-line chemo-
therapy, posttreatment disease status was characterized as
progressive or nonprogressive according to the overall
radiographic and clinical impression in the medical record.
We did not review imaging studies or use formal scales,
such as those of the World Health Organization or Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) for
this determination.
Statistical Analysis
Descriptive statistics (medians/means for continuous
variables and percentages for discrete variables) were gener-
ated for baseline demographic and clinical characteristics.
Both univariate and multivariate logistic regression models
were used to explore the association between demographic,
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disease, treatment characteristics, and receipt of second-line
chemotherapy. In these analyses, age was dichotomized as
less than 65 years and 65 years; year of diagnosis was
dichotomized as 2000–2003 and 2004–2007; and race/eth-
nicity was characterized as white (non-Hispanic) or other. In
the multivariate model, we included age, gender, race/ethnic-
ity, insurance type, number of cycles of first-line chemother-
apy, and prechemotherapy palliative radiation therapy. We
analyzed the association between demographic, disease and
treatment characteristics, receipt of second-line chemother-
apy, and overall survival using univariate and multivariate
Cox regression. Age, gender, race/ethnicity, insurance type,
number of cycles of first-line chemotherapy, prechemo-
therapy palliative radiation therapy, and administration of
second-line chemotherapy were included in the multivariate
model. All reported p values are two sided.
All statistical analyses were performed using SAS 9.2
Service Pack 4 for Windows (SAS Institute Inc., Cary, NC).
RESULTS
Study Population
From the tumor registries, we identified a total of 472
patients who received first-line chemotherapy. Of these pa-
tients, 66 received single-agent first-line therapy (39 received
a cytotoxic agent and 27 received an epidermal growth factor
receptor tyrosine kinase inhibitor) and were excluded from
the analysis. Within the remaining cohort of 406 patients, 186
(46%) were from PHHS, 153 (38%) were from the Dallas
VA, and 67 (16%) were from University Hospital. Mean age
was 59 years, 28% were women, and 59% were white.
Additional patient characteristics are listed in Table 1. Me-
dian follow-up was 9.4 months.
Specific years of diagnosis were as follows: 2000 (32
patients), 2001 (48), 2002 (53), 2003 (50), 2004 (60), 2005
(48), 2006 (63), and 2007 (52). Of the 132 patients listed as
“other” histology, three had large cell and 129 had NSCLC
not otherwise specified. Among the 121 patients who re-
ceived prechemotherapy palliative radiation therapy, the fol-
lowing sites were irradiated: brain (65 patients), lung (23
patients), bone (18 patients), brain and lung (nine patients),
brain and bone (five patients), and lung and bone (one
patient).
Second-Line Therapy Administration
Overall, 197 of 406 patients (49%) received second-
line chemotherapy. Of the 142 patients with nonprogres-
sive disease after four to six cycles of first-line chemo-
therapy, 95 (67%) received second-line chemotherapy. For
149 patients (76%), second-line chemotherapy was a cy-
totoxic agent. Forty-eight patients (24%) received an epi-
dermal growth factor receptor tyrosine kinase inhibitor as
second-line therapy.
In univariate analysis, insurance type, number of cycles
of first-line chemotherapy, and prechemotherapy palliative
radiation therapy were significantly associated with receipt of
second-line chemotherapy (Table 2). In multivariate analysis,
the following variables remained significantly associated with
second-line chemotherapy administration: insurance type
(p 0.003), number of cycles of first-line chemotherapy (OR
for4 cycles 0.24; 95% confidence interval [CI], 0.16–0.38;
p  0.001), and receipt of prechemotherapy palliative radi-
ation therapy (OR 0.51; 95% CI, 0.31–0.84; p  0.008).
Survival Analysis
In univariate analysis, overall survival was associated
with age (for 65 years, hazard ratio [HR] for death 0.76;
95% CI, 0.61–0.95; p  0.02), number of cycles of first-line
chemotherapy (for 4 cycles, HR for death 3.50; 95% CI,
2.82–4.34; p  0.001), and administration of second line
chemotherapy (if second-line chemotherapy received, HR for
death 0.41; 95% CI, 0.34–0.51; p  0.001). Overall survival
was not associated with gender, race/ethnicity, insurance
type, or receipt of prechemotherapy palliative radiation ther-
apy. In multivariate analysis, gender, number of cycles of
first-line chemotherapy, and receipt of second-line chemo-
therapy were associated with overall survival (Table 3 and
TABLE 1. Baseline Patient Characteristics
Characteristics
Mean (SD) or
Number (%)
Total number 406
Age (yr) 59.1  10.6
Gender
Male 294 (72.4)
Female 112 (27.6)
Race/ethnicity
Non-Hispanic white 238 (58.6)
African American 127 (31.3)
Hispanic 32 (7.9)
Other 9 (2.2)
Insurance type
Private insurance 91 (22.9)
No insurance 85 (21.4)
Medicaid 20 (5.0)
Medicare 47 (11.8)
VA 154 (38.8)
Year of diagnosis
2000–2003 182 (44.8)
2004–2007 224 (55.2)
Histology
Adenocarcinoma 168 (41.4)
Squamous cell 106 (26.1)
Other 132 (32.5)
Number of cycles of first-line chemotherapy
1–3 202 (49.8)
4 204 (50.2)
Nonprogressive after 4 cycles of first-line
chemotherapy
Yes 141 (34.7)
No 59 (14.5)
Not applicable 206 (50.7)
Prechemotherapy palliative radiation therapy
Yes 121 (30.0)
No 283 (70.0)
VA, Veterans Affairs.
Journal of Thoracic Oncology • Volume 6, Number 2, February 2011 Second-Line Chemotherapy for Advanced NSCLC
Copyright © 2011 by the International Association for the Study of Lung Cancer 367
Figure 1). For patients receiving fewer than four cycles of
first-line chemotherapy, median survival was 164 days (95%
CI, 146–185 days) compared with 495 days (95% CI, 431–
522 days) for patients receiving four or more cycles. Overall,
median survival was 185 days (95% CI, 159–206 days) for
patients who did not receive second-line chemotherapy, ver-
sus 472 days (95% CI, 419–522 days) for those who did
receive second-line treatment. When both variables were
considered, median overall survival was as follows: fewer
than four cycles of first-line chemotherapy without second-
line therapy (128 days; 95% CI, 117–146 days), fewer than
four cycles of first-line chemotherapy with second-line ther-
apy (274 days; 95% CI, 231–353 days), four or more cycles
of first-line chemotherapy without second-line therapy (329
days; 95% CI, 274–382 days), and four or more cycles of
first-line chemotherapy with second-line therapy (537 days;
95% CI, 503–601 days).
DISCUSSION
The recent wave of clinical trials examining the role of
maintenance chemotherapy for advanced NSCLC has again
placed a spotlight on the benefits of second-line chemother-
apy for this disease. Somewhat unexpectedly, these studies
have revealed widely varying rates of second-line chemother-
apy administration. In some studies, the likelihood of patients
randomized to observation after first-line chemotherapy re-
ceiving chemotherapy at the time of progression is below
20%,1 raising the possibility that broader use of second-
line therapies could mitigate some of the benefit attributed
to a maintenance approach. The study of immediate (i.e.,
maintenance) or delayed docetaxel after four cycles of
first-line therapy provides a prime example of this sce-
nario; overall survival for patients who received immediate
docetaxel and for the two thirds of patients randomized to
delayed docetaxel who ultimately received the assigned
treatment was identical.4
This study, which uses a contemporary, diverse, and
unselected population, offers further insight into the real-
world experience of second-line NSCLC treatment. In this
cohort, 67% of individuals who had not progressed after
receiving four cycles of first-line chemotherapy (i.e., those
patients considered candidates for maintenance chemother-
apy) ultimately received second-line treatment. Although this
rate itself is noteworthy for matching those reported in
TABLE 2. Association Between Baseline Characteristics and
Administration of Second-Line Chemotherapy (Univariate
Analysis)
Characteristics
Number (%)
Receiving
Second-Line
Chemotherapy
OR (95% CI)
for Receiving
Second-Line
Chemotherapy
Overall
p
Age
65 yr 137/287 (47.7) Reference 0.73
65 yr 59/119 (49.6) 1.08 (0.70–1.65)
Gender
Male 139/294 (47.3) Reference 0.51
Female 57/112 (50.9) 1.16 (0.75–1.79)
Race/ethnicity
Non-Hispanic white 116/238 (48.7) Reference 0.82
Other 80/168 (47.6) 0.96 (0.64–1.42)
Insurance type
Private insurance 55/91 (60.4) Reference 0.007
No insurance 37/85 (43.5) 0.51 (0.28–0.92)
Medicaid 7/20 (35.0) 0.35 (0.13–0.97)
Medicare 29/47 (61.7) 1.06 (0.51–2.17)
VA 63/154 (40.9) 0.45 (0.27–0.77)
Year of diagnosis
2000–2003 82/182 (45.1) 0.79 (0.53–1.17) 0.24
2004–2007 114/224 (50.9) Reference
Histology
Adenocarcinoma 88/168 (52.4) Reference 0.37
Squamous cell 47/106 (44.3) 0.72 (0.44–1.18)
Other 61/132 (46.2) 0.78 (0.50–1.23)
No. of cycles of
first-line
chemotherapy
1–3 64/202 (32.0) 0.26 (0.17–0.40) 0.001
4 131/204 (64.2) Reference
Prechemotherapy
palliative radiation
therapy
Yes 45/121 (37.2) 0.53 (0.34–0.82) 0.005
No 149/283 (52.7) Reference
CI, confidence interval; VA, Veterans Affairs.
TABLE 3. Association Between Demographics, Treatment
Characteristics, and Overall Survival (Multivariate Analysis)
Characteristics
HR (95% CI)
for Death
Overall
p
Age
65 yr Reference 0.14
65 yr 0.82 (0.63–1.07)
Gender
Male Reference 0.03
Female 0.75 (0.57–0.97)
Race/ethnicity
Non-Hispanic white Reference 0.25
Other 0.87 (0.70–1.10)
Insurance type
Private insurance Reference 0.46
No insurance 1.17 (0.85–1.60)
Medicaid 1.38 (0.83–2.30)
Medicare 1.40 (0.93–2.09)
VA 1.13 (0.82–1.55)
No. of cycles of first-line chemotherapy
1–3 3.16 (2.52–3.96) 0.001
4 Reference
Prechemotherapy palliative radiation
therapy
Yes 0.83 (0.65–1.05) 0.13
No Reference
Receipt of second-line chemotherapy
Yes 0.46 (0.37–0.58) 0.001
No Reference
CI, confidence interval; HR, hazard ratio; VA, Veterans Affairs.
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numerous maintenance therapy clinical trials,2,4,10 it must also
be placed into context. Our population likely includes many
individuals who, because of performance status, adherence to
medical care, or comorbidities, would not be candidates for
clinical trials. This study also examines second-line chemo-
therapy patterns among the larger population of all patients
with advanced NSCLC receiving first-line treatment. Com-
pared with the maintenance chemotherapy-eligible cohort,
patients who—because of disease progression, intolerable
toxicities, or nonadherence—did not receive four cycles of
first-line chemotherapy were substantially less likely to re-
ceive second-line chemotherapy (OR, 0.26).
This and earlier studies raise numerous questions. Why
is there such variation in rates of second-line chemotherapy
administration? What are the reasons patients do not receive
second-line therapy? Why does the rate of second-line che-
motherapy use in our series of unselected patients treated in
a relatively uncontrolled setting match or exceed that of
several prospective, randomized clinical trials? Although
there are no precise explanations, features of these clinical
trials may have contributed to these observations. One
study—in which disease progression was cited as the pre-
dominant reason why one-third of patients in the nonmainte-
nance arm did not receive second-line chemotherapy—used a
relatively long (3 months) interscan interval in the nonmain-
tenance arm, during which symptomatic progression and
associated clinical decline may have hindered administration
of second-line therapy.4 Another study—conducted in more
than 80 centers in 20 countries, throughout which second-
line practice patterns could vary considerably—left the
administration and selection of postprogression treatment
to the discretion of the investigator rather than mandating
second-line therapy for patients in the nonmaintenance
arm.10 A third study included a high proportion of patients
with poor performance status (80% Eastern Cooperative
Oncology Group 2).1
We found the following variables to be associated with
receipt of second-line chemotherapy: insurance type, number
FIGURE 1. Overall survival curves of patients categorized by number of cycles of first-line chemotherapy (A), receipt of sec-
ond-line chemotherapy (B), and both the number of cycles of first-line chemotherapy and receipt of second-line chemother-
apy (C).
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of cycles of first-line chemotherapy, and receipt of palliative
radiation therapy before first-line chemotherapy administra-
tion. In a previous study of a similar patient cohort, we found
that older patients with advanced NSCLC were less likely to
receive first-line chemotherapy,18 presumably because older
individuals tend to be more frail and have more medical
comorbidities. It seems logical that age would not be associ-
ated with receipt of second-line chemotherapy in the same
population because those older patients not fit for chemother-
apy have already been selected out of the present study
cohort. These observations echo those of a subset analysis of
the phase III trial of second-line pemetrexed versus do-
cetaxel, in which elderly patient participation was similar to
rates observed in the first-line setting.19 By contrast, we found
insurance type to predict receipt of both first-line treatment18
and second-line treatment. Although reasons for this ongoing
association throughout the entire disease course are not evi-
dent from either study, it seems possible that insurance
type—a surrogate marker of socioeconomic status—could be
associated not only with performance status and comorbidi-
ties but also with treatment preferences and adherence to
medical care, factors that continue to impact populations well
beyond first-line chemotherapy. Year of diagnosis was not
associated with second-line chemotherapy administration, al-
though we had expected to see an increase after 2004, when
results of phase III trials of second-line erlotinib and pem-
etrexed, as well as second-line docetaxel quality of life data,
were presented.8,9,20
Our use of prechemotherapy palliative radiation ther-
apy as a predictive variable also merits comment. We se-
lected this unconventional metric as a potential marker of
disease burden and severity. It represents a diverse group of
patients, including those with brain metastases; clinically
significant hemoptysis or airway compromise; and refractory
pain, neurologic sequelae, or skeletal instability from bony
metastases. It is possible that these patients represent a
population at subsequent risk for a more symptomatic, com-
plex clinical course. It follows that these patients are substan-
tially less likely to receive second-line chemotherapy (OR,
0.53 in this study). It seems less likely that prechemotherapy
palliative radiation therapy itself—either by the delay in
initiation of systemic therapy or through radiation-associated
toxicities—accounts for the reduced rate of second-line che-
motherapy administration.
Both the number of cycles of first-line chemotherapy
and the receipt of second-line chemotherapy were indepen-
dently associated with overall survival. Although no conclu-
sions about the effect of these treatment factors on clinical
endpoints can be drawn from this observational, nonrandom-
ized trial, these findings may provide insight into overall
outcomes. We selected a cutoff of four cycles of first-line
chemotherapy because this number implies clinical effect (as
radiographic studies assessing response to therapy are typi-
cally performed every two cycles), acceptable toxicity profile,
and patient adherence to treatment. Among patients who
ultimately received second-line chemotherapy, median sur-
vival was 17.9 months for those who received four or more
cycles of first-line chemotherapy, when compared with 8.7
months for those who received fewer than four cycles of
first-line chemotherapy. These findings echo those of earlier
studies, in which response to first-line chemotherapy was an
independent predictor of receipt of second-line chemothe-
rapy11 and overall survival.21
Limitations of this study include its retrospective na-
ture, its single academic center setting, and relatively small
sample size. Despite the retrospective design, disease and
treatment follow-up data were available until patient death for
more than 95% of the cohort. Because of the geographical
setting and variety of UT Southwestern-affiliated clinical
facilities, our patient cohort is racially and socioeconomically
diverse. Nonetheless, certain patient populations, such as East
Asians, are underrepresented. Furthermore, the physicians
caring for these individuals are predominantly academic tho-
racic oncologists, who may be more likely to use second-line
chemotherapy than are other practitioners. That stated, the
ability of these physicians to deliver second-line chemother-
apy to two thirds of this largely socioeconomically chal-
lenged cohort suggests that it may be feasible in most other
U.S. settings as well. Finally, reasons why second-line che-
motherapy was not administered were not available.
In conclusion, in this unselected, diverse cohort of
patients with advanced NSCLC, approximately 50% of pa-
tients who received first-line chemotherapy eventually re-
ceived second-line chemotherapy. Limiting the analysis to
those individuals whose disease did not progress after four to
six cycles of first-line chemotherapy—the population eligible
for maintenance chemotherapy—the rate rises to 67%, a
figure that meets or exceeds those of numerous recent clinical
trials. Markers of socioeconomic status, symptom burden,
and response to and tolerance of first-line chemotherapy were
associated with receipt of second-line chemotherapy. Main-
tenance chemotherapy trials have highlighted critical eco-
nomic and quality of life issues. The cost per life-year gained
from maintenance pemetrexed exceeds $120,000.22 Although
approved maintenance agents such as pemetrexed and erlo-
tinib are generally well tolerated, there is clearly a subset of
patients who maintain prolonged disease control after first-
line chemotherapy with no subsequent treatment—and who
then successfully receive second-line therapy at the time of
progression. It follows that identifying those patients least
likely to receive second-line chemotherapy might guide the
selective use of maintenance chemotherapy, thereby limiting
both costs and toxicities. Based on the findings in this study,
socioeconomically disadvantaged patients and patients with
greater symptom burden—manifest by the need for preche-
motherapy palliative radiation therapy—may represent such a
target population.
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